Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
Zymeworks (ZYME) Stock Price & Analysis
450 Followers
ZYME Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.02 - $13.14
Previous Close$10.3
Volume468.42K
Average Volume (3M)569.62K
Market Cap
$733.56M
Enterprise Value$385.86M
Total Cash (Recent Filing)$374.33M
Total Debt (Recent Filing)$26.63M
Price to Earnings (P/E)-5.9
Beta0.66
Next Earnings
May 01, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding70,568,222
10 Day Avg. Volume638,932
30 Day Avg. Volume569,620
Standard Deviation0.16
R-Squared0.14
Alpha-0.00383
Financial Highlights & Ratios
Price to Book (P/B)1.73
Price to Sales (P/S)9.56
Price to Cash Flow (P/CF)13.20
P/FCF Ratio15.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.08
Enterprise Value/Gross Profit5.08
Enterprise Value/Ebitda-3.79
Forecast
1Y Price Target
$13.93Price Target Upside32.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Zymeworks News
PremiumCompany Announcements
Zymeworks Announces Upcoming Financial Report
PremiumCompany Announcements
Zymeworks Unveils Promising Cancer Research
PremiumCompany Announcements
Zymeworks CFO Dr. Astle Exits with Severance PackagePremiumCompany Announcements
Zymeworks Announces Executive Shake-Up, Appoints Interim CFOPremiumCompany Announcements
Zymeworks Inc. Strengthens Board with Dr. Gallagher’s Appointment
PremiumCompany Announcements
Zymeworks Bolsters Board with Oncology ExpertRisk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $6.01 and its highest was $13.14 in the past 12 months.
What is Zymeworks Inc’s market cap?
Currently, no data Available
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is May 01, 2024 which is in 13 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Mar 06, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.415 by $0.215.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is -$0.32.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 70,568,220 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.415. Following the earnings report the stock price went down -6.46%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Among the largest hedge funds holding Zymeworks Inc’s share is Farallon Capital Management, L.L.C.. It holds Zymeworks Inc’s shares valued at 18M.
---
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.93 (32.41% Upside)
$13.93 (32.41% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 685.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $428.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.35%
12-Months-Change
Fundamentals
Return on Equity
-24.78%
Trailing 12-Months
Asset Growth
-10.46%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
---
ZYME Earnings Call
Q4 2024
0:00 / 0:00
---
ZYME Stock 12 Months Forecast
Average Price Target
$13.93
▲(32.41% Upside)
Technical Analysis
Best Analysts Covering ZYME
1 Year
1 Year Success Rate
12/13 ratings generated profit
1 Year Average Return
+42.41%
reiterated a buy rating 5 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +42.41% per trade.
---